Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Type Condition

    Nashville, TN

    Search
    Nashville, TN
    Show Map
    Map View
    Nashville, TN
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      209 Clinical Paid Trials near Nashville, TN

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      D3S-001 for KRAS Mutation-related Cancer

      Nashville, Tennessee
      This trial tests a new drug, D3S-001, taken daily for a few weeks, in patients with certain advanced cancers. The drug aims to block a faulty part of the cancer cells to stop or slow their growth.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Disease, Gastrointestinal Conditions, Others

      442 Participants Needed

      Abemaciclib + Elacestrant for Brain Metastasis from Breast Cancer

      Nashville, Tennessee
      This trial tests a combination of two drugs, elacestrant and abemaciclib, in patients with a specific type of breast cancer. It aims to find the best dose and see how well it works for those whose cancer has spread to the brain. The drugs work by blocking signals that help cancer cells grow and divide. Abemaciclib is a drug that has been approved for the treatment of certain advanced breast cancers.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Leptomeningeal Metastases, Concurrent Malignancy, Others
      Must Not Be Taking:CYP3A4 Inducers/inhibitors, Herbal Meds

      73 Participants Needed

      NVL-655 for NSCLC

      Nashville, Tennessee
      This trial is testing a new drug called NVL-655 to see if it is safe and effective for patients with advanced ALK-positive lung cancer and other solid tumors. The drug works by blocking a protein that helps cancer cells grow. The study focuses on patients who have specific genetic changes and may not respond well to standard treatments. Newer treatments have been shown to improve outcomes in ALK-translocated lung cancer compared to older treatments.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Other Oncogenic Driver, Allergy, Others
      Must Not Be Taking:Anticancer Therapy

      840 Participants Needed

      RMC-6236 for Cancer

      Nashville, Tennessee
      This trial is testing a new drug called RMC-6236, which is taken by mouth and targets a protein called RAS. It is aimed at adults with advanced cancers that have specific mutations in the RAS protein. The drug works by blocking this protein, which helps stop the cancer cells from growing.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Tumors, Brain Metastases, GI Impairment, Others

      754 Participants Needed

      Amivantamab + Chemotherapy for Colorectal Cancer

      Nashville, Tennessee
      This trial is testing a new medicine called amivantamab on patients with advanced colorectal cancer. The medicine helps the immune system find and destroy cancer cells. Researchers want to see how well it works alone and with standard chemotherapy.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:KRAS, NRAS, BRAF, EGFR, Others

      225 Participants Needed

      Bemarituzumab for Solid Cancers

      Nashville, Tennessee
      This trial is testing bemarituzumab, a new medication, to see if it is safe and can help fight tumors in patients, especially when other treatments have not worked well. Bemarituzumab has been previously studied for certain types of cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Cardiac Disease, Ophthalmologic Disorders, Others
      Must Not Be Taking:Anti-arrhythmics, Ophthalmic Steroids

      260 Participants Needed

      Tiragolumab + Atezolizumab for Solid Tumors

      Nashville, Tennessee
      This trial studies how well tiragolumab and atezolizumab work in children and adults with difficult-to-treat tumors missing specific genes. These treatments help the immune system attack cancer and stop it from growing. Atezolizumab is an antibody that has been used with other treatments for various cancers.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Active Autoimmune, Hepatitis, Others
      Must Not Be Taking:Systemic Steroids, Immunosuppressants

      86 Participants Needed

      TNG908 for Solid Tumors

      Nashville, Tennessee
      This trial is testing TNG908, an oral drug, in patients with advanced or metastatic solid tumors that have an MTAP deletion. The drug works by blocking a protein that helps these specific cancer cells grow. The study will see if this treatment can help slow down or stop the cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Liver Disease, Cardiovascular, Others
      Must Not Be Taking:Antiretrovirals

      192 Participants Needed

      JBI-802 for Solid Tumors

      Nashville, Tennessee
      The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JBI-802 in patients with Advanced Solid Tumors.The efficacy of the RP2D will be evaluated in phase 2 in patients with solid tumors of neuroendocrine differentiation.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Disease, Heart Failure, Others
      Must Not Be Taking:CYP3A Inhibitors, CYP3A Inducers, CYP2D6 Inhibitors, CYP2D6 Inducers

      126 Participants Needed

      Relatlimab + Nivolumab for Lymphoma

      Nashville, Tennessee
      This trial is testing two drugs, relatlimab and nivolumab, in children and young adults whose lymphoma has come back or didn't respond to other treatments. These drugs help the immune system recognize and attack cancer cells. The study aims to see if this combination is safe and effective. Nivolumab has demonstrated clinical benefits in multiple tumors, including classical Hodgkin lymphoma.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:< 30

      Key Eligibility Criteria

      Disqualifiers:CNS Lymphoma, Autoimmune Disease, Others
      Must Not Be Taking:Anti-CTLA-4, LAG-3 Agents

      68 Participants Needed

      BLU-222 for Solid Cancers

      Nashville, Tennessee
      This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Visceral Crisis, CNS Metastases, ILD, Others
      Must Not Be Taking:CDK2 Inhibitors

      366 Participants Needed

      GEN1047 for Cancer

      Nashville, Tennessee
      This trial tests GEN1047, a new medicine that helps the immune system fight cancer, in patients with different types of solid tumors. The study aims to find a safe dose and see if it works well.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Impairment, Brain Metastases, Pneumonitis, Others
      Must Not Be Taking:Steroids

      179 Participants Needed

      CAR T-Cell Therapy for Non-Hodgkin's Lymphoma

      Nashville, Tennessee
      A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin's Lymphoma.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Lymphoma, Autoimmune Disease, Others
      Must Not Be Taking:Anti-CD79a Therapy

      15 Participants Needed

      NVL-520 for ROS1-Positive Solid Tumors

      Nashville, Tennessee
      This trial tests NVL-520, a new drug, for safety and effectiveness in patients with advanced ROS1-positive cancers. It targets those who haven't responded well to other treatments by blocking a protein that helps cancer cells grow. NVL-520 is being tested for its effectiveness in treating advanced ROS1-positive cancers, a targetable mutation in non-small cell lung cancer (NSCLC) that has seen various treatments like crizotinib and entrectinib.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Other Oncogenic Drivers, Allergy, Major Surgery, Others

      359 Participants Needed

      BAY2927088 for Non-Small Cell Lung Cancer

      Nashville, Tennessee
      This trial is testing a new drug called BAY2927088 for people with advanced lung cancer. The drug aims to block certain proteins that help cancer grow. Researchers want to find out how safe the drug is, the best dose to use, and how well it works in stopping cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Heart Failure, HIV, Others
      Must Not Be Taking:Strong CYP3A4 Inhibitors, Inducers

      370 Participants Needed

      Selinexor + Radiation for Brain Cancer

      Nashville, Tennessee
      This trial tests the safety and effectiveness of combining selinexor with radiation therapy in children and young adults with aggressive brain tumors. Selinexor is a drug that blocks a protein to stop cancer cells from growing. The study aims to find the best dose and see if this combination can shrink tumors.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:12 - 21

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Infection, Organ Transplant, Others
      Must Not Be Taking:Investigational Drugs, Anti-cancer Agents

      132 Participants Needed

      ASP1570 + Pembrolizumab for Advanced Cancer

      Nashville, Tennessee
      This trial is testing ASP1570, a new drug that helps the immune system fight cancer by reactivating T-cells. It targets adults with advanced solid tumors that have spread and are not responding to standard treatments. ASP1570 works by counteracting the signals that tumors use to turn off T-cells. The study will determine the best dose and test its effectiveness alone or with another drug called pembrolizumab.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, CNS Metastases, Others
      Must Not Be Taking:CYP2D6 Inhibitors, Steroids

      366 Participants Needed

      TransCon IL-2 β/γ + Pembrolizumab/Chemotherapy for Solid Tumor Cancers

      Nashville, Tennessee
      This trial is testing a new drug called TransCon IL-2 β/γ for adults with advanced or spreading solid tumors. The drug aims to boost the immune system to better fight cancer by slowly releasing a molecule that helps immune cells attack cancer cells. TransCon IL-2 β/γ is a new long-acting drug currently being evaluated.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Autoimmune Diseases, Cardiac Disease, Others
      Must Not Be Taking:Immunosuppressants, IL-2 Variants

      345 Participants Needed

      Elimusertib for Solid Cancers

      Nashville, Tennessee
      This trial tests elimusertib, a pill that blocks enzymes needed for cancer cell growth, in children and young adults with difficult-to-treat cancers. The drug aims to stop cancer cells from repairing and growing.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:12 - 30

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Active CNS Metastasis, Infection, Others
      Must Not Be Taking:CYP3A4 Drugs

      31 Participants Needed

      ARV-766 +/- Abiraterone for Prostate Cancer

      Nashville, Tennessee
      This trial is testing a new oral drug called ARV-766, alone or with abiraterone, in men with advanced prostate cancer that has spread. The drug works by blocking proteins that help cancer cells grow. Abiraterone is a well-established drug used in the treatment of metastatic castration-resistant prostate cancer, often in combination with other therapies.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Gastrointestinal Disease, Others
      Must Be Taking:Androgen Deprivation Therapy

      152 Participants Needed

      Why Other Patients Applied

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40
      Match to a Trial

      ERAS-007 Combination Therapy for Gastrointestinal Cancer

      Nashville, Tennessee
      This trial is testing a new drug called ERAS-007 combined with other cancer treatments to see if it is safe and effective for patients with advanced gastrointestinal cancers. The study focuses on patients with specific genetic mutations in their cancer cells, which are often hard to treat. ERAS-007 aims to target these mutations to help stop the cancer from growing.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Symptomatic Brain Metastasis, Active Infection, Cardiovascular Disease, Others
      Must Not Be Taking:RAS Inhibitors

      102 Participants Needed

      BGB-16673 for B-Cell Cancers

      Nashville, Tennessee
      This trial tests a new drug called BGB-16673 to find the best dose for patients. It aims to determine how well the drug works and its safety. The study involves finding the right dose and expanding testing to more patients.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Prior Malignancy, CNS Involvement, Others
      Must Be Taking:BTK Inhibitors

      614 Participants Needed

      Tovorafenib + Pimasertib for Cancer

      Nashville, Tennessee
      This trial is testing Tovorafenib, a drug that blocks proteins needed for cancer cell growth, in patients aged 12+ with hard-to-treat melanoma or other solid tumors.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Activating Mutation, CSR, RVO, Others
      Must Not Be Taking:RAS-RAF-MEK-ERK Inhibitors

      168 Participants Needed

      LY3537982 for Cancer

      Nashville, Tennessee
      This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Infection, Cardiac Condition, Autoimmune, Others
      Must Not Be Taking:Steroids, KRAS Inhibitors

      540 Participants Needed

      AZD7789 for Cancer

      Nashville, Tennessee
      This trial is testing a new medicine called AZD7789 that helps the immune system fight advanced solid tumors by blocking proteins that hide cancer cells. It aims to see if the medicine is safe and effective for patients whose cancer has progressed despite other treatments.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:EGFR Mutations, ALK Fusions, Others
      Must Be Taking:Anti-PD-1/PD-L1

      136 Participants Needed

      Taletrectinib for Non-Small Cell Lung Cancer

      Nashville, Tennessee
      This trial is testing taletrectinib, a new drug, in patients with advanced lung cancer that have a specific genetic change. Taletrectinib is taken orally and aims to stop cancer growth by blocking this genetic change.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Other Malignancy, Lung Disease, Infections, Others
      Must Not Be Taking:CYP3A4/5 Inhibitors, QT Prolonging

      217 Participants Needed

      BMS-986340 + Nivolumab/Docetaxel for Cancer

      Nashville, Tennessee
      This trial tests a new drug, BMS-986340, alone and with other cancer treatments (nivolumab and docetaxel) in patients with advanced solid tumors. The goal is to find out if it is safe and effective in treating these cancers.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, CNS Malignancy, Autoimmune, Others
      Must Not Be Taking:Corticosteroids, Immunosuppressives

      949 Participants Needed

      MCLA-129 for Non-Small Cell Lung Cancer

      Nashville, Tennessee
      This trial tests a new drug, MCLA-129, on its own in patients with advanced cancers who did not respond to previous treatments. The study will adjust doses to find the safest and most effective amount.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Cardiovascular Disease, Others
      Must Not Be Taking:Steroids, Anticancer, Immunotherapy, Others

      576 Participants Needed

      ERAS-007 + ERAS-601 for Advanced Cancer

      Nashville, Tennessee
      * To evaluate the safety and tolerability of ERAS-007 monotherapy administered once weekly (QW) and twice daily-once weekly (BID-QW). * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 monotherapy administered BID-QW. * To characterize the pharmacokinetic (PK) profile of ERAS-007 monotherapy. * To determine the optimal dose and schedule of ERAS-007 monotherapy. * To evaluate antitumor activity of ERAS-007 in various solid tumors. * To evaluate the safety and tolerability of ERAS-007 (BID-QW) and ERAS-601 (twice daily for three weeks on and 1 week off (BID 3/1)) when administered in combination. * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with ERAS-601. * To characterize the pharmacokinetic (PK) profile of ERAS-007 and ERAS-601 when administered in combination. * To evaluate antitumor activity of ERAS-007 and ERAS-601 when administered in combination in various solid tumors * To evaluate antitumor activity of ERAS-007 and ERAS-601 when administered in combination in various solid tumors
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, Gastrointestinal Dysfunction, Others
      Must Not Be Taking:ERK Inhibitors, SHP2 Inhibitors, MAPK Inhibitors

      200 Participants Needed

      1...67

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do clinical trials in Nashville, TN pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in Nashville, TN work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Nashville, TN 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Nashville, TN is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Nashville, TN several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in Nashville, TN?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in Nashville, TN?

      Most recently, we added HMPL-A251 for Cancer, NBM-BMX for Eye Cancer and Gene Therapy for HER2 Positive Cancer to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in Tennessee

      Anxiety Clinical Trials in Tennessee

      Schizophrenia Clinical Trials in Tennessee

      ADHD Clinical Trials in Tennessee

      Bipolar Disorder Clinical Trials in Tennessee

      Multiple Sclerosis Clinical Trials in Tennessee

      Autism Clinical Trials in Tennessee

      Treatment Resistant Depression Clinical Trials in Tennessee

      Borderline Personality Disorder Clinical Trials in Tennessee

      Social Anxiety Disorder Clinical Trials in Tennessee

      Parkinson's Disease Clinical Trials in Tennessee

      Alzheimer's Disease Clinical Trials in Tennessee

      By Location

      Clinical Trials near Nashville, TN

      Clinical Trials near Memphis, TN

      Clinical Trials near Knoxville, TN

      Clinical Trials near Chattanooga, TN

      Clinical Trials near Germantown, TN

      Clinical Trials near Kingsport, TN

      Clinical Trials near Jackson, TN

      Clinical Trials near Bristol, TN

      Clinical Trials near Johnson City, TN

      Clinical Trials near Franklin, TN

      Clinical Trials near Cordova, TN

      Clinical Trials near Murfreesboro, TN

      Other People Viewed

      By Subject

      225 Clinical Trials near Nashville, TN

      16 Eczema Trials near Nashville, TN

      213 Clinical Trials near Knoxville, TN

      210 Clinical Trials near Humboldt, TN

      119 Clinical Trials near Johnson City, TN

      210 Clinical Trials near Collierville, TN

      16 Multiple Sclerosis Trials near Knoxville, TN

      214 Clinical Trials near Chattanooga, TN

      Top Clinical Trials near Cordova, TN

      Top Clinical Trials near Crossville, TN

      Top Clinical Trials near Chattanooga, TN

      Top Clinical Trials near Brentwood, TN

      By Trial

      PF-06838435 for Hemophilia B

      RSV Vaccine for Older Adults

      mRNA Vaccine for RSV

      PDS with Ranibizumab vs. Intravitreal Ranibizumab for Diabetic Macular Edema

      Vaccine for Respiratory Syncytial Virus

      Apixaban for Cancer

      Isatuximab Combination Therapy for Multiple Myeloma

      TAK-700 vs. Bicalutamide for Prostate Cancer

      FOLFOXIRI + Bevacizumab for Colorectal Cancer

      RSV Vaccines for Respiratory Syncytial Virus

      ASTX727 for Leukemia

      Vaccine for Zika

      Related Searches

      Top Treatment for Lenalidomide Clinical Trials

      Smartphone Flicker Fusion Test for Vision Impairment

      Naltrexone for Alcoholism

      Exercise Intervention for Obesity and Sarcopenia

      Water-Based Exercise + Cognitive Training for Mild Cognitive Impairment

      Ide-cel (bb2121) for Multiple Myeloma

      Aerobic Exercise for Multiple Sclerosis

      Laruparetigene Zovaparvovec for Retinitis Pigmentosa

      Talquetamab + Iberdomide + Dexamethasone for Multiple Myeloma

      Personalized Medication for Severe Ulcerative Colitis

      Cervigard Neck Collar for Neck Pain

      Upadacitinib for Eczema